Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0714.1973.tb01671.x | DOI Listing |
Narra J
December 2024
Department of Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
Skin aging is one of the degenerative processes influenced by tyrosinase, elastase, collagenase, hyaluronidase, and matrix metalloproteinase-9 (MMP9) activity. One promising avenue for discovering antiaging therapeutics is the peptides from the spine. The aim of this study was to explore the potential of peptides from spine as a multitarget inhibitor for recombinant antiaging therapies through in silico approaches.
View Article and Find Full Text PDFIn Silico Pharmacol
January 2025
College of Chemistry and Chemical Engineering, China University of Petroleum, Qingdao, 266580 China.
Matrix metalloproteinase-8 (MMP-8), a type II collagenase, is a key enzyme in the degradation of collagens and is implicated in various pathological processes, making it a promising target for drug discovery. Despite advancements in the development of MMP-8 inhibitors, concerns over potential adverse effects persist. This study aims to address these concerns by focusing on the development of novel compounds with improved safety profiles while maintaining efficacy.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Pittsburgh Heart, Lung and Blood Vascular Medicine Institute (VMI), University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA.
Matrix metalloproteinase-2 (MMP-2), a zinc-dependent enzyme, plays a critical role in the degradation and remodeling of the extracellular matrix (ECM). As a member of the gelatinase subgroup of matrix metalloproteinases, MMP-2 is involved in a variety of physiological processes, including tissue repair, wound healing, angiogenesis, and embryogenesis. It is primarily responsible for the degradation of type IV and V collagen, fibronectin, laminin, and elastin, which are essential components of the ECM.
View Article and Find Full Text PDFDev Cell
December 2024
Institut Curie, CNRS UMR 144, PSL University, 75005 Paris, France. Electronic address:
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently hyperactivated in triple-negative breast cancers (TNBCs) associated with poor prognosis and is a therapeutic target in breast cancer management. Here, we describe the effects of repression of mTOR-containing complex 1 (mTORC1) through knockdown of several key mTORC1 components or with mTOR inhibitors used in cancer therapy. mTORC1 repression results in an ∼10-fold increase in extracellular matrix proteolytic degradation.
View Article and Find Full Text PDFAm J Transl Res
November 2024
Lower Extremity Division, Orthopedic Trauma Department, Honghui Hospital, Xi'an Jiaotong University Youyi East Road No. 555, Beilin District, Xi'an, Shaanxi, China.
Purpose: The stromal cell protein metalloproteinase 9 (MMP9), associated with extracellular matrix degradation and remodeling, promotes tumor invasion and metastasis and regulates cell adhesion molecule and cytokine activity. This study evaluated MMP9 in pan-cancer and screened for compounds and drug candidates that can inhibit it.
Methods: MMP9 expression in pan-cancer tissues was evaluated in a pan-cancer dataset from the University of California Santa Cruz database, along with the correlation between MMP9 and the tumor microenvironment (TME), RNA modification genes, and tumor mutation burden.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!